02:29:29 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-06-05 Bokslutskommuniké 2024
2024-02-29 Kvartalsrapport 2024-Q3
2024-02-26 Halvårsutdelning EKTA B 1.2
2023-11-30 Kvartalsrapport 2024-Q2
2023-08-25 Halvårsutdelning EKTA B 1.2
2023-08-24 Årsstämma 2024
2023-08-24 Kvartalsrapport 2024-Q1
2023-05-25 Bokslutskommuniké 2023
2023-02-24 Halvårsutdelning EKTA B 1.2
2023-02-24 Kvartalsrapport 2023-Q3
2022-11-24 Kvartalsrapport 2023-Q2
2022-08-26 Halvårsutdelning EKTA B 1.2
2022-08-25 Årsstämma 2023
2022-08-25 Kvartalsrapport 2023-Q1
2022-05-25 Bokslutskommuniké 2022
2022-02-24 Kvartalsrapport 2022-Q3
2022-02-24 Halvårsutdelning EKTA B 1.1
2021-11-25 Kvartalsrapport 2022-Q2
2021-08-26 Halvårsutdelning EKTA B 1.1
2021-08-25 Kvartalsrapport 2022-Q1
2021-08-25 Årsstämma 2022
2021-05-28 Bokslutskommuniké 2021
2021-04-19 Bonusutdelning EKTA B 0.9
2021-04-16 Extra Bolagsstämma 2021
2021-02-25 Kvartalsrapport 2021-Q3
2020-11-26 Kvartalsrapport 2021-Q2
2020-08-27 Halvårsutdelning EKTA B 0.9
2020-08-26 Årsstämma 2021
2020-08-26 Kvartalsrapport 2021-Q1
2020-05-29 Bokslutskommuniké 2020
2020-02-21 Halvårsutdelning EKTA B 0.9
2020-02-20 Kvartalsrapport 2020-Q3
2019-11-28 Kvartalsrapport 2020-Q2
2019-08-23 Halvårsutdelning EKTA B 0.9
2019-08-22 Årsstämma 2020
2019-08-22 Kvartalsrapport 2020-Q1
2019-05-29 Bokslutskommuniké 2019
2019-03-01 Halvårsutdelning EKTA B 0.7
2019-02-22 Kvartalsrapport 2019-Q3
2018-11-29 Kvartalsrapport 2019-Q2
2018-08-31 Halvårsutdelning EKTA B 0.7
2018-08-30 Kvartalsrapport 2019-Q1
2018-08-30 Årsstämma 2019
2018-06-01 Bokslutskommuniké 2018
2018-03-02 Kvartalsrapport 2018-Q3
2018-02-22 Halvårsutdelning EKTA B 0.5
2017-11-30 Kvartalsrapport 2018-Q2
2017-08-24 Halvårsutdelning EKTA B 0.5
2017-08-23 Årsstämma 2018
2017-08-23 Kvartalsrapport 2018-Q1
2017-06-01 Bokslutskommuniké 2017
2017-03-03 Halvårsutdelning EKTA B 0.25
2017-03-01 Kvartalsrapport 2017-Q3
2016-12-01 Kvartalsrapport 2017-Q2
2016-09-26 Kapitalmarknadsdag 2016
2016-09-02 Halvårsutdelning EKTA B 0.25
2016-09-01 Årsstämma 2017
2016-09-01 Kvartalsrapport 2017-Q1
2016-06-01 Bokslutskommuniké 2016
2016-03-02 Kvartalsrapport 2016-Q3
2015-12-03 Kvartalsrapport 2016-Q2
2015-09-02 Ordinarie utdelning EKTA B 0.50 SEK
2015-09-01 Kvartalsrapport 2016-Q1
2015-09-01 Årsstämma 2016
2015-06-02 Bokslutskommuniké 2015
2015-03-04 Kvartalsrapport 2015-Q3
2014-11-27 Kvartalsrapport 2015-Q2
2014-11-27 Analytiker möte 2014
2014-09-15 Kapitalmarknadsdag 2014
2014-08-29 Ordinarie utdelning EKTA B 1.50 SEK
2014-08-29 Bonusutdelning EKTA B 0.5
2014-08-28 Kvartalsrapport 2015-Q1
2014-08-28 Analytiker möte 2015
2014-08-28 Årsstämma 2015
2014-05-28 Analytiker möte 2014
2014-05-28 Bokslutskommuniké 2014
2014-02-27 Kvartalsrapport 2014-Q3
2013-12-04 Kvartalsrapport 2014-Q2
2013-09-23 Kapitalmarknadsdag 2013
2013-09-04 Ordinarie utdelning EKTA B 1.50 SEK
2013-09-04 Bonusutdelning EKTA B 0.5
2013-09-03 Kvartalsrapport 2014-Q1
2013-09-03 Årsstämma 2014
2013-06-05 Bokslutskommuniké 2013
2013-06-05 Analytiker möte 2013
2013-03-05 Extra Bolagsstämma 2013
2013-03-05 Kvartalsrapport 2013-Q3
2012-12-04 Kvartalsrapport 2013-Q2
2012-10-29 Kapitalmarknadsdag 2012
2012-09-12 Split EKTA B 1:4
2012-09-05 Ordinarie utdelning EKTA B 5.00 SEK
2012-09-03 Årsstämma 2013
2012-09-03 Kvartalsrapport 2013-Q1
2012-06-05 Analytiker möte 2012
2012-06-05 Bokslutskommuniké 2012
2012-04-02 Extra Bolagsstämma 2012
2012-03-05 Kvartalsrapport 2012-Q3
2011-12-02 Kvartalsrapport 2012-Q2
2011-09-14 Ordinarie utdelning EKTA B 4.00 SEK
2011-09-13 Årsstämma 2012
2011-09-13 Kvartalsrapport 2012-Q1
2011-06-09 Bokslutskommuniké 2011
2011-03-08 Kvartalsrapport 2011-Q3
2010-12-07 Kvartalsrapport 2011-Q2
2010-09-22 Ordinarie utdelning EKTA B 3.00 SEK
2010-09-21 Kvartalsrapport 2011-Q1
2010-06-09 Bokslutskommuniké 2010
2010-03-10 Kvartalsrapport 2009-Q3
2009-12-10 Kvartalsrapport 2009-Q2
2009-09-16 Ordinarie utdelning EKTA B 2.00 SEK
2009-09-15 Årsstämma 1
2009-09-15 Kvartalsrapport 2009-Q1
2008-09-19 Ordinarie utdelning EKTA B 1.75 SEK
2007-09-26 Ordinarie utdelning EKTA B 1.00 SEK
2006-09-21 Ordinarie utdelning EKTA B 1.00 SEK
2005-10-17 Split EKTA B 1:3
2005-09-22 Ordinarie utdelning EKTA B 6.60 SEK
2004-09-22 Ordinarie utdelning EKTA B 0.00 SEK
2003-09-23 Ordinarie utdelning EKTA B 0.00 SEK
2002-10-01 Ordinarie utdelning EKTA B 0.00 SEK
2001-09-28 Ordinarie utdelning EKTA B 0.00 SEK
2000-10-02 Ordinarie utdelning EKTA B 0.00 SEK
1999-09-23 Ordinarie utdelning EKTA B 0.00 SEK

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Elekta är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av kliniska lösningar för behandling av cancer och hjärnsjukdomar. Elektas behandlingssystem och planeringsmjukvara för strålterapi och strålkirurgi samt övriga mjukvarusystem används inom sjukhusindustrin för att identifiera och analysera olika hälsotillstånd. Verksamhet innehas på global nivå, med huvudkontor i Stockholm.
2020-07-22 07:30:00

SYDNEY, Australia, July 22, 2020 - Elekta (EKTA-B.ST) announced today that the GenesisCare oncology center at St. Vincent's Hospital (Sydney, New South Wales) has started treating patients with Elekta Unity, a radiation therapy system that allows doctors to see a tumor's movements and its exact position during the delivery of therapeutic radiation. St. Vincent's is the first site of 21 eventual Elekta Unity installations in GenesisCare's global network to initiate clinical use of the system.

In early July the first patient, a 63-year-old man, received treatment for prostate cancer. Since then, the oncology center has also started treating individuals with oligometastatic disease.

"The ability to capture crystal clear images of tumors and their exact boundaries and movements using Elekta Unity has been critical in maximizing the effectiveness of radiotherapy, while also minimizing toxicity," says Jeremy de Leon, MD, GenesisCare's MR-Linac lead radiation oncologist.

He adds that the system represents a major evolution of cancer treatment in Australia. "It significantly enhances our capability to adapt therapy planning to account for daily treatment-related or other anatomical changes," he says. "That means each patient's treatment session can be individually personalized for his or her needs. GenesisCare radiation oncologists have always strived for this, but now they have the ultimate tool to help them accomplish it."

GenesisCare CEO Dan Collins added: "More than ever in these challenging times, we want to ensure that cancer patients all around the world receive the right care when it's needed. This is why we are continuing our investment in the latest technology through our partnership with Elekta.

"The Elekta Unity is a significant step forward for patients with complex cancers. Our goal to increase access to this innovative technology starts at St Vincent's in Sydney, Australia and will extend through our international network, which includes more than 400 cancer treatment centers in Europe and now the USA. Our wonderful physicians and team members across GenesisCare are passionate innovators, and this system will allow them to realize outcomes for patients beyond what has been possible before. We will also foster new research, techniques and innovation based around the huge potential of MR radiation therapy."

"GenesisCare has always been a leader in patient care and healthcare innovation in the many markets it serves around the world," says Shaun Seery, Elekta's Senior Vice President Asia Pacific, Global Marketing & Sales Excellence. "Their adoption of Elekta Unity systems for their global network is evidence of that and represents another important validation of the potential of magnetic resonance guided radiation therapy."

Elekta Unity is a state-of-the art MR-Linac that is defining a new standard for personalized radiation therapy based on real-time high resolution anatomical and biological MRI at the point-of-care. Unity combines a Philips high-field 1.5T MRI scanner with a best-in-class 7MV linear accelerator and breakthrough online dose replanning software that are fully integrated to enable adaptive radiotherapy and real-time target monitoring.

To learn more about Elekta Unity, visit elekta.com/Unity (http://www.elekta.com/unity).

# # #

For further information, please contact:
Mattias Thorsson, Vice President, Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com  
Time zone: CET: Central European Time

Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time

About GenesisCare
Sydney-headquartered GenesisCare delivers treatment to people with cancer and heart disease, the two largest disease burdens globally. They're committed to leading the change in how care is given and are leading or participating in more than 150 clinical trials. The organization employs more than 5,500 highly trained physicians, healthcare professionals and support staff across Australia, Europe, and now the U.S. This follows GenesisCare's acquisition of major U.S. integrated oncology provider 21[st] Century Oncology in May 2020.

Every year GenesisCare clinical teams see more than 400,000 people at more than 440 locations. For cancer treatment, that includes more than 300 locations in the U.S., 38 locations in Australia, 14 in the UK and 21 in Spain, with more than 30 new centers under development. The organization also offers cardiology and sleep services at more than 80 locations across Australia. Their purpose is to design care experiences that get the best possible life outcomes. For more information visit www.genesiscare.com

About GenesisCare and Elekta's partnership
Over the past year, GenesisCare announced the acquisition of a further 20 Elekta Unity machines, which will be rolled out in Australia, the United States and Europe, over the coming years. To coincide with the acquisition of the machines, GenesisCare and Elekta announced a strategic partnership to advance the ongoing clinical development of adaptive therapy based on real-world evidence. The partnership will see GenesisCare and Elekta work together to create standardized data repositories that advance adaptive therapy technologies and create a platform to assess the clinical value of radiotherapy.

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com (http://www.elekta.com) or follow @Elektaon Twitter